S
Salomon Manier
Researcher at Harvard University
Publications - 168
Citations - 4550
Salomon Manier is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 30, co-authored 115 publications receiving 3276 citations. Previous affiliations of Salomon Manier include French Institute of Health and Medical Research & university of lille.
Papers
More filters
Journal ArticleDOI
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier,Karma Salem,Karma Salem,Jihye Park,Jihye Park,Dan A. Landau,Gad Getz,Irene M. Ghobrial,Irene M. Ghobrial +8 more
TL;DR: This Review describes the 'driver' gene alterations involved in the development and progression of MM, with a focus on the sequential acquisition of the main genomic aberrations and provides valuable insight into the clonal heterogeneity and clonal evolution of the disease.
Journal ArticleDOI
Targeting the bone marrow microenvironment in multiple myeloma
Yawara Kawano,Michele Moschetta,Salomon Manier,Siobhan Glavey,Gullu Gorgun,Aldo M. Roccaro,Kenneth C. Anderson,Irene M. Ghobrial +7 more
TL;DR: The interaction between the malignant plasma cell and the BM microenvironment and the strategy to target them is discussed.
Journal ArticleDOI
Bone marrow microenvironment in multiple myeloma progression.
TL;DR: How the interaction between the malignant plasma cell and the BM microenvironment allowed myeloma progression through cell homing and the new concept of premetastatic niche is discussed.
Journal ArticleDOI
Engineered nanomedicine for myeloma and bone microenvironment targeting
Archana Swami,Michaela R. Reagan,Pamela Basto,Yuji Mishima,Nazila Kamaly,Siobhan Glavey,Sufeng Zhang,Michele Moschetta,Dushanth Seevaratnam,Yong Zhang,Jinhe Liu,Masoumeh Memarzadeh,Jun Wu,Salomon Manier,Jinjun Shi,Nicolas Bertrand,Zhi Ning Lu,Kenichi Nagano,Roland Baron,Antonio Sacco,Aldo M. Roccaro,Omid C. Farokhzad,Irene M. Ghobrial +22 more
TL;DR: Bone-homing, stealth nanoparticles to deliver anticancer, bone-stimulatory drugs, and demonstrated their utility with bortezomib and multiple myeloma models suggest that NP-based anticancer therapies with bone-targeting specificity comprise a clinically relevant method of drug delivery that can inhibit tumor progression in MM.
Journal ArticleDOI
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie D. Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Darrell White,Daniel Binder,Jin Lu,Kenneth C. Anderson,Philippe Moreau,Michel Attal,Aurore Perrot,Bertrand Arnulf,Lugui Qiu,Murielle Roussel,Eileen M Boyle,Salomon Manier,Mohamad Mohty,Hervé Avet-Loiseau,Xavier Leleu,Annette Ervin-Haynes,Guang Chen,Vanessa Houck,Lotfi Benboubker,Cyrille Hulin +38 more
TL;DR: Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible multiple myeloma.